ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

ODX Omega Diagnostics Group Plc

2.20
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Omega Diagnostics Group Plc LSE:ODX London Ordinary Share GB00B1VCP282 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.20 2.00 2.40 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Omega Diagnostics Share Discussion Threads

Showing 1101 to 1123 of 37200 messages
Chat Pages: Latest  48  47  46  45  44  43  42  41  40  39  38  37  Older
DateSubjectAuthorDiscuss
07/7/2015
08:12
Different set of problems... becomes unstable after 5 weeks in storage at room temperature (is that in the UK lab or in a hut in sub saharan africa). Disappointing to say the least.
spacecake
07/7/2015
08:12
Lol hi Barry only a matter of waiting till things sorted don't know why people panic you would think they are a one product company
leedslad001
07/7/2015
08:04
Morning All,

Well that went well!!!!

barrywhit
02/7/2015
12:33
The 7th July should be informative and may give us a timeline for progress.

I added yesterday and perhaps there may be a small run up to the results.

pdt
28/6/2015
15:38
Results 7th July should get a full update
leedslad001
16/6/2015
12:02
Omega Diagnostics’ Group Scientific Director, Nigel Abrahams, discusses the key differences between allergy and intolerance, explains the differences between IgE and IgG, and introduces Food Detective™, the world's first self test for food intolerance, at medicine-based gluten & FIT seminar in Hong Kong.

…/hxxp://beikebiotech.com/blog/2015/06/02/beike-hosts-functional-medicine-based-gluten-food-intolerance-seminar-in-hong-kong/

I like the worlds first bit. So much depth to this company.

leedslad001
15/6/2015
17:32
Looks like the share price is heading south to greece.
spacecake
10/6/2015
14:57
??? were to now !!
farmsted
05/6/2015
11:11
Morning All,

All heading in the right direction, I thought the 100k buy the other day would have been a Director buy, obviously not, well done Richard Sneller...

barrywhit
05/6/2015
10:41
Richard Sneller has heavily increased his stake in ODX to 4.4m from his prior disclosure in March last year of 3.3m and is now above 4%:



Interestingly, he seems to be a Fund Manager at Baillie Gifford, so knows his way around small companies:

rivaldo
05/6/2015
08:25
Performing well at present. Lots to go for still though.
rivaldo
02/6/2015
16:04
Old article but shows the quantity of testing potentially available to ODX,
barrywhit
01/6/2015
19:17
A profit is always a profit. Can't begrudge someone selling when they want to.
longshanks
01/6/2015
18:49
Their name says it all!!!!

No wonder we didn't keep the rise looking at the last 2 delayed sells....

barrywhit
01/6/2015
18:20
Did anyone read that Motley Fool article - where do they get these muppets from??
longshanks
01/6/2015
09:15
Longshanks / Barrywhit - thanks for your replies, appreciated.

If it hits 50p in 12 months time I would be delighted.

pdt
01/6/2015
08:50
We may well see Broker Note upgrades after todays RNS.....
barrywhit
01/6/2015
08:42
Can't buy in any volume, looks like some-one is buying in 5k batches....
barrywhit
01/6/2015
08:34
CE approval won't take long - it should be a fairly straightforward process; there are no moving parts or child usage issues.Field trials could take 3-4 months - so I would pencil in limited sales (if any) for this FY. But this is all about FY16+ and the sales growth should be rapid. Margins will be very high and it should turn a very decent profit that will go straight to the bottom line.ISYS based sales of allergens will be less profitable but will add another good string to what is already a fairly diverse bow of commercial operations.The new COO appointment is a good sign too as where CD4 leads, other potential markets are available for the Visitek handheld device: he will be key to developing those markets/opportunities IMO.Long term - this has £1+ written all over it. I agree bw - we could see Director purchases now that news is out.
longshanks
01/6/2015
08:22
PDT,

Difficult to say after field trials the company will need to obtain CE Approval...but this is a very big step forward....imo

barrywhit
01/6/2015
08:14
Morning, I am new here, could someone advise how long the next step is likely to take before commercialisation ? The news release stated;

"will now be subject to verification and validation leading to the release of Visitect(R) CD4 test devices for re-evaluation in the field."

Six months? A year? or longer. Thanks.

Nice professional thread here.

pdt
01/6/2015
08:07
Could be that we will now see a few director buys......
barrywhit
01/6/2015
08:05
Hard to pick up any in quantity this morning. Mms appear to have closed the doors.
longshanks
Chat Pages: Latest  48  47  46  45  44  43  42  41  40  39  38  37  Older

Your Recent History

Delayed Upgrade Clock